Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$32.40-4.37%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Amylyx is advancing its lead drug AMX0035 with promising trial progress. The company aims to maintain cash runway into 2028. It is developing a new drug candidate AMX0318 for rare diseases. Recent pipeline progress supports potential future growth.
Amylyx remains loss-making with negative EPS guidance near -$0.46 per share in 2025. Recent earnings misses and ongoing litigation pose risks. The company has no revenue guidance and uncertain commercial success.
The stock trades about 47% below our fair value near $34, reflecting high risk. The market expects continued losses and slow progress. Our fair value aligns with the Street median, but the price discounts much of the turnaround hope.
Breaks if: AMX0318 development stalls or is discontinued
Breaks if: Cash runway falls short of 2028 based on operating plans
EPS remains below -$0.46 or worsens through FY27
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis state is cautious, as recent financial performance has been weak, but there are potential catalysts ahead.
The market seems to have a low fragility tier, indicating that it does not currently expect significant volatility. However, expectations are tempered due to the company's ongoing losses and recent earnings misses.
Fundamentals may remain under pressure in the near term, especially given the company's loss-making status and elevated risks. Management is focused on key priorities, such as submitting a New Drug Application (NDA) and maintaining cash runway, but execution will be critical.
The long-term thesis hinges on several factors, including the company's ability to submit the NDA on time, the performance of sector peers, and the overall economic environment impacting healthcare stocks. Any guidance cuts or continued weakness in the jobs report could negatively affect sentiment.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company made progress on avexitide's launch. This supports its timeline for submitting the NDA in 2027. However, it missed earnings expectations recently. This miss raises concerns about its financial performance.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Over the next 1 to 3 years, AMLX's trajectory will depend on successful execution of its strategic priorities and external market conditions. Not investment advice.